- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03279770
Circulating Non-coding RNAs and Cardiovascular Outcomes in Patients With Dyslipidemia and Atherosclerosis
Cardiovascular diseases and stroke are the major causes of morbidity and death in Taiwan. There is a clear need to identify novel mediators of atherosclerosis in dyslipidemic patients to provide insights into the pathogenesis, to tailor clinical care based on cardiovascular risks, and to develop new therapeutic strategies.
While the roles of lncRNAs in human diseases including cancer and neurodegenerative disorders are beginning to emerge, it remains unclear how lncRNA regulation contributes to atherosclerotic vascular diseases in patients with dyslipidemia. In this proposal, we seek to apply next-generation sequencing technology to investigate circulating (plasma and peripheral blood mononuclear cells [PBMC]) lncRNA expression in control subjects and in dyslipidemic patients with and without atherosclerotic vascular diseases (CAD, ischemic stroke and PAOD). The results from these experiments will lead to better understanding of how circulating lncRNAs contribute to atherosclerotic cardiovascular complications.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Cardiovascular diseases and stroke are the major causes of morbidity and death in Taiwan. Patients with dyslipidemia are prone to atherosclerosis, which predispose to various cardiovascular pathology including coronary artery disease (CAD), ischemic stroke and peripheral artery occlusive disease (PAOD). There are, however, no reliable biomarkers to detect atherosclerotic vascular diseases among dyslipidemic patients or to predict the risks of cardiovascular morbidities and mortality among patients with atherosclerosis. There is a clear need to identify novel mediators of atherosclerosis in dyslipidemic patients to provide insights into the pathogenesis, to tailor clinical care based on cardiovascular risks, and to develop new therapeutic strategies.
It has become increasingly clear that the transcription of the eukaryotic genome is far more pervasive and complex than previously appreciated. While the expression of messenger RNAs (mRNAs) and microRNAs (miRNAs) account for only ~1% of all transcribed species, up to 90% of the mammalian genome is transcribed as long non-coding RNAs (lncRNAs), a heterogeneous group of non-coding transcripts longer than 200 nucleotides. LncRNAs have been shown to be functional and involved in specific physiological and pathological processes through epigenetic, transcriptional and post-transcriptional mechanisms. While the roles of lncRNAs in human diseases including cancer and neurodegenerative disorders are beginning to emerge, it remains unclear how lncRNA regulation contributes to atherosclerotic vascular diseases in patients with dyslipidemia.
In this proposal, we seek to apply next-generation sequencing technology to investigate circulating (plasma and peripheral blood mononuclear cells [PBMC]) lncRNA expression in control subjects and in dyslipidemic patients with and without atherosclerotic vascular diseases (CAD, ischemic stroke and PAOD). We will test the hypothesis that circulating lncRNA expression signature can reflect the atherosclerotic disease states in patients with dyslipidemia. A gene co-expression network analysis will be conducted to identify lncRNAs that are functionally involved in the pathogenesis of atherosclerosis. With the experimental results from an initial dyslipidemic cohort, we will establish an atherosclerosis scoring model on the basis of circulating lncRNA expression signature to facilitate the detection of atherosclerotic vascular diseases in patients with dyslipidemia. The accuracy, sensitivity and specificity of the lncRNA-based atherosclerosis scoring system will then be tested in an independent, large validation cohort. Next, we propose to test the hypothesis that circulating lncRNAs can be novel prognostic biomarkers to predict atherosclerosis progression and cardiovascular outcomes in dyslipidemic patients. The results from these experiments will lead to better understanding of how circulating lncRNAs contribute to atherosclerotic cardiovascular complications. These studies will also establish a set of novel, lncRNA-based diagnostic and prognostic biomarker in dyslipidemic patients to improve clinical preventive and therapeutic care. In addition, the findings from these studies will help to develop novel therapeutic strategies to treat or prevent atherosclerotic vascular diseases in patients with dyslipidemia.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Luoghi di studio
-
-
-
Taipei, Taiwan, 100
- Reclutamento
- National Taiwan University Hospital
-
Contatto:
- Kai-Chien Yang, M.D. Ph.D.
- Numero di telefono: 88327 +886223123456
- Email: kcyang@ntu.edu.tw
-
Investigatore principale:
- Chau-Chung Wu, M.D. Ph.D.
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Dyslipidemia: Total cholesterol (TC) >200 mg/dL; LDL-C > 130 mg/dL ; TG > 200 mg/dL; male HDL-C < 40 mg/dL, female HDL-C < 50 mg/dL, or under lipid lowering therapy
Atherosclerotic vascular disease:
- Coronary atherosclerosis as evidenced by cardiac catheterization examination, having history of myocardial infarction as evidenced by ECG or hospitalization, angina patient showing ischemic ECG changes or positive response to stress test;
- Cerebral vascular disease, cerebral infarction, intracerebral hemorrhage (excluding intracerebral hemorrhage associated with other diseases); transient ischemic attack (TIA) with carotid artery ultrasound confirming atheromatous change with more than 70% blockage;
- Peripheral atherosclerosis with symptoms of ischemia and confirmed by Doppler ultrasound or angiography in history.
- Control subjects: Age, gender-matched healthy adults without dyslipidemia and atherosclerotic diseases will be recruited as control subjects.
Exclusion Criteria The main exclusion criteria will be hemodynamically significant valvular or congenital heart disease, life-threatening malignancy, treatment with immunosuppressive agents, or any condition or situation which, in the opinion of the investigator, might be not suitable for this registration.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Esito cardiovascolare composito
Lasso di tempo: fino a 5 anni
|
L'esito cardiovascolare composito (CV) sarà qualsiasi evento CV (malattie vascolari coronariche, cerebrali o periferiche)
|
fino a 5 anni
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Chau-Chung Wu, M.D., Ph. D., National Taiwan University Hospital
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 201505165RINC
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .